Document Detail

Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
MedLine Citation:
PMID:  23331529     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: Subcutaneous immunoglobulin (SCIG) therapy is gaining favor for the management of primary immunodeficiency disease (PIDD) in adults and children.
METHODS: A retrospective chart review captured data on 96 pediatric patients with PIDD using SCIG (16% or 20%) delivered by infusion pump or SC rapid push over 620 clinic visits. Patients previously using intravenous immunoglobulin (IVIG) were converted to SCIG dosing on a 1:1 basis. Patients/caregivers voluntarily chose an administration technique.
RESULTS: Although mean SCIG dosing was lower on a g/kg/month basis compared with prior IVIG dosing, mean steady-state serum IgG levels during SCIG administration were about 100-200 mg/dl higher than IVIG trough values. On average, much more rapid infusion was achieved with the SC rapid push method, with 49% of patients reporting infusion times of 9 min or less; median duration of infusion pump administration was 45 min. The use of 20% SCIG increased dosing efficiency compared with 16% SCIG, allowing for a smaller weekly mean SCIG volume and fewer dosing days per week. Adverse event (AE) rates were lower in the pediatric subgroup compared with adults (15.8% vs. 18.8% of visits), and the majority of AEs were local. SC rapid push was reported most frequently for patients under age 2; its use decreased between ages 2 and <10 yr and then increased in adolescence and into adulthood. Only one of the pediatric patients returned to IVIG use.
CONCLUSIONS: Administration of replacement Ig via SC rapid push is a safe and viable option in pediatric patients with PIDD.
Ralph S Shapiro
Related Documents :
23388479 - Comparison of the anti-inflammatory and therapeutic actions of ppar-gamma agonists rosi...
24129129 - The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
24856989 - Glucocorticoid treatment in rheumatoid arthritis.
23380829 - Optimizing asparaginase therapy for acute lymphoblastic leukemia.
23987199 - Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication...
19756749 - Biological control of sheep gastrointestinal nematodiasis in a tropical region of the s...
8543979 - Continuous intravenous infusion of iodine-123-ibzm for spect determination of human bra...
1297639 - Clinical pharmacokinetics of teicoplanin and aminophylline during cotreatment with both...
3133339 - Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology     Volume:  24     ISSN:  1399-3038     ISO Abbreviation:  Pediatr Allergy Immunol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9106718     Medline TA:  Pediatr Allergy Immunol     Country:  England    
Other Details:
Languages:  eng     Pagination:  49-53     Citation Subset:  IM    
Copyright Information:
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
Midwest Immunology Clinic, Plymouth, MN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children.
Next Document:  Herpesvirus infections and allergic sensitization in children of families with anthroposophic and no...